Evolutionary cytokines, Revolutionary medicines

Medicenna is a clinical stage immunotherapy company that uses directed evolution to generate engineered interleukins called Superkines that can modulate, fine-tune or amplify the immune system in order to combat the most challenging diseases and inspire hope in patients with unmet needs.


At the core of Medicenna’s therapies are engineered interleukins designed to improve upon the specificity, function, and safety profile of unmodified interleukins. These powerful and proprietary therapies are known as Superkines, and can modulate, fine-tune or amplify the immune system to fight cancer, autoimmune or neuroinflammatory diseases. Our approach allows us the flexibility to transform Superkines into multi-functional therapies that can be delivered directly to where they are needed the most. Medicenna’s initial focus is on developing interleukin-2 (IL-2), IL-4 and IL-13 super-agonists and antagonists.


Oct 24 – Oct 25, 2020

Emergence of Novel Long-acting Mono- and Bi-specific IL-2/IL-13 Superkines as Potent Immune Modulators



Oct 26, 2020

Medicenna Presents Promising Preclinical Data on IL-2 and IL-13 Superkines at the EORTC-NCI-AACR Annual Meeting